AGILE Home

AGILE

AGILE is a national multidisciplinary research collaborative bringing together researchers, consumers, clinicians and partner organisations to optimise health and wellbeing for people taking GLP-1 medications.

Why AGILE?

GLP-1 medications are rapidly transforming the management of obesity and related chronic conditions, but evidence on how best to optimise health and wellbeing alongside treatment remains limited. Key questions remain about how to support nutrition, physical activity, muscle and bone health, psychological wellbeing and long-term behaviour change.

AGILE aims to generate the research evidence needed to maximise the health and wellbeing benefits of GLP-1 medications, minimise potential harms and support equitable access to effective healthy living care for sustainable improvements in health and quality of life.

Led by the University of Melbourne, AGILE brings together complementary research and clinical experts, people with lived experience and partner organisations to accelerate research, inform clinical practice and shape future models of equitable, high-quality care in Australia and internationally.